PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...
Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines Eligible Manulife customers in Hong Kong ...
Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
17don MSN
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia
Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health announced the launch of its Shield multi-cancer detection/MCD test in several Asian ...
HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ -- Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...
PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Mar 16, 2026-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results